Chronic liver injury from alpha-1 antitrypsin deficiency leads to both scarring (cirrhosis) and an increased risk of liver cancer (hepatocellular carcinoma). The deficiency causes misfolded A1AT to accumulate in hepatocytes, provoking ongoing inflammation and fibrosis that can progress to cirrhosis. Once cirrhosis develops, the risk of hepatocellular carcinoma rises due to the chronic regenerative drive and genetic instability in the cirrhotic liver. Therefore, this condition is associated with both cirrhosis and hepatocellular carcinoma, with the cancer risk being greatest when cirrhosis is present.

Right-sided infective endocarditis sends vegetations into the venous circulation, so fragments embolize to the lungs via the pulmonary arteries. This makes septic pulmonary emboli the classic and most likely complication. Emboli to the brain, spleen, or kidneys come from left-sided endocarditis, since those emboli travel through the arterial system to systemic organs. In practice, right-sided disease (often involving the tricuspid valve) is classically associated with pulmonary findings, whereas systemic emboli point to left-sided involvement.

Direct oral anticoagulants, such as apixaban or rivaroxaban, are preferred for long-term management of deep vein thrombosis. They provide effective protection against recurrent events with a convenient, fixed dosing approach and do not require routine lab monitoring or warfarin-like INR management. They also avoid the need for bridging with heparin, which simplifies outpatient therapy. Trials have shown these DOACs to be as effective as warfarin for preventing recurrence, with at least comparable or even lower risk of major bleeding. In contrast, heparin is mainly for initial treatment, warfarin requires regular INR checks and has many interactions, and aspirin alone does not offer adequate anticoagulation for long-term prevention in most patients.

Obtaining fluid from the pleural space with thoracentesis provides material for direct analysis and is the first, best step to diagnose a new pleural effusion. By tapping the effusion, you can send pleural fluid for multiple tests that distinguish causes and guide management: Light’s criteria to separate exudates from transudates, cell counts with differential, cytology for malignancy, Gram stain and culture for infection, pH and glucose levels, and even ADA testing for TB. This direct sampling is what makes thoracentesis the most informative initial intervention. Chest imaging can show that an effusion is present but does not yield diagnostic fluid. Lung biopsy samples tissue, not fluid, and bronchoscopy targets the airways rather than the pleural space, so they don’t provide the diagnostic pleural fluid needed to evaluate the effusion.